Data Sheet 1: CD38 Enzymatic Activity Modulation in Multiple Myeloma Therapy

Alberto L. Horenstein's figshare document analyzes CD38 enzymatic activity during antibody-based immunotherapy for multiple myeloma. The 2.0 MB DOCX file, last updated in April 2026, presents in vitro and in vivo findings on NAD+ degradation and adenosine metabolite dynamics. It discusses the role of adenosinergic immunosuppression in therapeutic resistance.

Use Cases

• Analyze CD38 enzymatic function and NAD+ degradation based on the described in vitro experiments.
• Investigate adenosine and inosine metabolite dynamics in bone marrow plasma based on the described in vivo patient data.
• Model adenosinergic immunosuppression and its contribution to a tolerogenic niche based on the discussion of P1 purinergic receptor thresholds.
• Evaluate the rationale for combining CD38-targeted antibodies with adenosinergic signaling inhibitors based on the study's conclusions.

Strengths

• The document provides a detailed scientific perspective on a specific clinical challenge in multiple myeloma.
• It includes analysis of both in vitro cell line data and in vivo patient plasma data from bone marrow and peripheral blood.
• The file is licensed under CC-BY-4.0, permitting open sharing and adaptation.

Limitations

• The dataset is a single DOCX document; the underlying raw data (columns, rows, sample data) is unavailable.
• Row count is unknown, which may limit suitability assessment for quantitative analysis.
• Column-level documentation is absent; field semantics must be inferred from the textual description.

Provenance

Source

Alberto L. Horenstein via figshare.

Collection Method

Likely contains results from laboratory experiments and clinical sample analysis.

Freshness

Last updated 2026-04-29 05:41:32; freshness should be verified.